3 results
The primary objective of this trial is to compare the effect of three different doses of ONO-8539 with placebo in the mean change of the number of micturitions per 24 hrs from baseline to 12 weeks.The secondary objectives of this trial will be:*To…
Primary:To characterize the dose response of nemiralisib administered in addition to SoC (standard of care) compared with placebo and SoC in participants diagnosed with an acute moderate or severe exacerbation of COPD. Secondary:Dose response and…
Phase 1b:Primary:- To evaluate the safety and tolerability and determine the recommended Phase 2 dose (RP2D) and schedule of ALRN-6924 when administered to patients with TP53-mutated extensive disease (ED) small cell lung cancer (SCLC) receiving…